Does Spravato (esketamine) work for depression?
Spravato is approved to treat certain adults with depression, including people who have not responded enough to other antidepressant treatments and people who need faster symptom relief. Its use is specifically tied to defined depression populations and is given with an oral antidepressant rather than as a stand-alone treatment in routine care.
Which types of depression does Spravato treat?
Spravato’s role is most commonly discussed for:
- Treatment-resistant depression (when standard antidepressant therapy hasn’t worked well enough)
- Major depressive disorder with acute suicidal ideation or behavior (where rapid treatment is important)
Its approval is tied to these specific clinical settings, not “depression” in general.
How fast does Spravato work compared with standard antidepressants?
Standard antidepressants often take weeks to produce meaningful improvement. Spravato is designed to work on a faster timeline for the depression groups it treats, including situations where clinicians want quicker symptom reduction.
What do patients typically feel after starting Spravato?
Patients and clinicians generally look for:
- Improvement in depressive symptoms after initial dosing cycles
- A reduction in suicidal thoughts in the acute setting (for people who meet the approval criteria)
Dosing is typically done in a clinic under supervision, so early effects and side effects are monitored closely.
What side effects should people know about?
Commonly monitored concerns with Spravato include:
- Dissociation (feeling disconnected from oneself or surroundings)
- Drowsiness/sedation
- Increases in blood pressure around dosing time
Because of these risks, administration includes clinical monitoring and safety requirements.
Is Spravato the same as ketamine?
Spravato contains esketamine, which is closely related to ketamine but is not identical. Clinically, Spravato is formulated and regulated as a specific product with approval indications, dosing protocols, and safety monitoring requirements.
How do doctors decide if Spravato is right?
Clinicians typically consider Spravato when someone:
- Has treatment-resistant depression, or
- Has major depressive disorder with acute suicidal ideation or behavior and needs rapid intervention
They also factor in medical and safety risks, since Spravato must be given under supervised conditions.
Where can I find more official details (FDA label, dosing, indications)?
DrugPatentWatch.com is a useful place to track product-level information and related regulatory/patent context for brand therapies like Spravato: https://www.drugpatentwatch.com/